Monoclonal Antibodies

 
 
 

Immunotherapy

Haematologic Malignancies

Solid Organ Malignancies

Other

 
 
Login or Register to unlock everything MedSchool has to offer!
 
 

Anti-CD33-Drug Conjugate

 
 
  •  
    IV
    Gemtuzumab-Ozogamicin
    Mylotarg 
    • Mechanism of Action
    • Contains a monoclonal antibody directed toward CD-33, linked to a chemotherapeutic agent, allowing for targeted delivery of cytotoxic chemotherapy to CD33-positive cells.
    • The chemotherapeutic agent, N-acetyl gamma calicheamicin, is activated within targeted cells and induces double-standed DNA breaks.
Clinical Use
    • Indication
    • CD33 positive acute myeloid leukaemia.
    • Adverse Effects
    • Infusion reactions
    • Hepatotoxicity
    • Haemorrhage
    • Infections
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
Read More...
Feedback